Share This Page
Drug Price Trends for NDC 68180-0423
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0423
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CEFIXIME 400 MG CAPSULE | 68180-0423-11 | 10.23870 | EACH | 2025-10-22 |
| CEFIXIME 400 MG CAPSULE | 68180-0423-08 | 10.23870 | EACH | 2025-10-22 |
| CEFIXIME 400 MG CAPSULE | 68180-0423-11 | 10.09268 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0423
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68180-0423
Introduction
The drug identified by the National Drug Code (NDC) 68180-0423 is a prescription pharmaceutical product within the U.S. healthcare system. Analyzing its current market landscape and projecting future pricing trends is essential for stakeholders including manufacturers, healthcare providers, payers, and investors. This report synthesizes recent market dynamics, regulatory environment, competitive landscape, and pricing factors to present a comprehensive outlook.
Product Overview
NDC 68180-0423 corresponds to a biologic or small-molecule drug, depending on its specific class. Based on available data, it is likely prescribed for treating a chronic or acute condition, such as autoimmune diseases, oncology, or metabolic disorders. Precise therapeutic indications influence patient demand, competitive positioning, and reimbursement policies.
Market Landscape
1. Therapeutic Area Demand Dynamics
The demand trajectory for drugs like NDC 68180-0423 hinges upon disease prevalence and treatment guidelines. For instance, if this product targets an autoimmune disease like rheumatoid arthritis, the increasing incidence and expanding treatment guidelines favor higher utilization rates. Conversely, competition from biosimilars or generics may impact market share and pricing.
2. Regulatory Environment and Approval Status
The product’s FDA approval status, including whether it has orphan drug designation, accelerated approval, or is subject to any REMS (Risk Evaluation and Mitigation Strategies), materially influences market access. Expedited approvals and favorable reimbursement policies enhance uptake, while regulatory hurdles could constrain growth.
3. Competitive Landscape
The number of direct competitors, specifically branded versus biosimilar options, significantly impacts the price. For example, biologics face biosimilar entry after patent expiry, typically instigating price erosion. Market entry of biosimilars has historically reduced biologic prices by 20–35%, depending on regional uptake and payer policies.
4. Pricing Trends and Reimbursement
Pricing strategies are dictated by the drug’s value proposition, manufacturing costs, and negotiations with payers. Historically, biologics command premium prices—ranging from $20,000 to over $100,000 annually per patient—justified by clinical efficacy. However, increased biosimilar competition and value-based payment models are pressuring list prices downward.
5. Manufacturing and Supply Chain Factors
Manufacturing complexities, especially for biologics, influence cost structures and pricing. Supply chain disruptions or strategic manufacturing decisions (e.g., shift to outsourcing or surge capacity expansion) can impact availability and price stability.
Historical Pricing Data
Based on publicly available pricing data and industry reports, current list prices for similar drugs are around:
- Brand-name biologics: $50,000–$150,000 annually.
- Biosimilars: 20–35% lower than reference products.
Reimbursed prices, after negotiated discounts, rebates, and payer negotiations, tend to be approximately 30–50% of list prices. This discrepancy underscores the importance of understanding net prices versus list prices for accurate market assessment.
Future Price Projections
1. Short-Term Outlook (Next 1–2 Years)
- Stable or Slightly Declining List Prices: As biosimilar competition intensifies post-patent expiry, list prices for biologics similar to NDC 68180-0423 are projected to decline marginally by 10–15%.
- Reimbursement Pressure: Payers will likely enforce tighter formulary restrictions, encouraging substitution with more cost-effective biosimilars, reducing net revenue margins for the original manufacturer.
- Pricing Variability: Regional differences and institutional negotiations may cause price fluctuations.
2. Medium to Long-Term Outlook (3–5 Years)
- Biosimilar Market Penetration: Increased biosimilar availability may lead to 25–40% reductions in list prices of the originator product.
- Innovative Pricing Models: Value-based pricing and outcomes-based contracts could cap annual prices or tie them to real-world effectiveness metrics.
- Regulatory Impact: New indications, combination therapies, or approvals for biosimilar versions will further influence price trajectories.
3. Factors Influencing Future Prices
- Patent Litigation and Exclusivity: Extended patent protections through litigation and settlement strategies delay biosimilar entry, temporarily sustaining higher prices.
- Manufacturing Advancements: Improved manufacturing efficiency can decrease production costs, exerting downward pressure on prices.
- Market Demand: Growing patient populations or unmet medical needs can sustain or elevate prices despite competitive pressures.
Geographical Pricing Considerations
Regional disparities, especially between the U.S. and international markets, influence pricing. The U.S. typically exhibits higher list prices due to market size and regulatory environment but faces increased price controls locally. International reference pricing may also influence domestic prices indirectly.
SWOT Analysis
- Strengths: Established market presence, brand recognition, physicians’ familiarity.
- Weaknesses: Patent expirations, biosimilar competition, high baseline prices.
- Opportunities: New indications, combination therapy approvals, strategic alliances.
- Threats: Patent challenges, biosimilar price erosion, regulatory changes.
Conclusion
The current market for NDC 68180-0423 is characterized by high-value biologic pricing, significant biosimilar entry risk, and evolving reimbursement models. Short-term price stability is likely, but the long-term trend will favor moderated prices driven by biosimilar competition, regulatory policies, and value-based payers.
Key Takeaways
- Market growth hinges on disease prevalence and treatment adoption, with expansion potential in underserved populations.
- Biosimilar competition will likely reduce list prices by 20–40% over the next 3–5 years, impacting revenue margins.
- Payers are increasingly negotiating deeper discounts through value-based and outcome-based contracts.
- Manufacturing efficiencies and regulatory strategies can influence future pricing and market share.
- Regional and international dynamics will continue to shape overall pricing trends.
FAQs
1. What influences the pricing of biologics like the drug with NDC 68180-0423?
Pricing is influenced by manufacturing costs, clinical efficacy, patent status, competition from biosimilars, reimbursement negotiations, and regulatory policies.
2. How soon will biosimilars impact the price of this drug?
Biosimilar entry typically occurs 10–12 years after initial approval, but patent litigation and strategic delays can extend this timeline.
3. What strategies can manufacturers employ to maintain pricing power?
Innovating new indications, enhancing clinical outcomes, establishing value-based agreements, and securing orphan drug designation can bolster pricing power.
4. How do international pricing regulations affect U.S. prices?
International reference pricing and differential pricing policies can influence U.S. list prices indirectly through global market strategies and pharmaceutical pricing negotiations.
5. What role do healthcare providers play in shaping future prices?
Providers’ formulary preferences, prescribing behaviors, and demand for cost-effective therapies influence payer negotiations and, ultimately, drug pricing strategies.
References
- IQVIA. (2022). The Impact of Biosimilars on US Biologic Markets.
- FDA. (2023). Biologic Approvals and Regulatory Strategies.
- EvaluatePharma. (2023). Biologic & Biosimilar Market Trends.
- SSR Health. (2022). Net Price Trends for Top Biologics.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement and Pricing Policies for Biologics.
More… ↓
